ARNA Genomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ARNA Genomics is a private, pre-revenue diagnostics company developing a proprietary liquid biopsy platform for early cancer detection. Its lead program, ARNA Breast, is an assay for early-stage breast cancer currently in development and clinical trials. The company boasts a scientifically distinguished leadership team, including inventor Anatoly Melnikov and renowned scientist Dr. Charles R. Cantor, and is headquartered in Orange County, California.

Oncology

Technology Platform

Proprietary multiomics liquid biopsy platform focusing on whole-genome DNA methylation analysis and novel DNA amplification/hybridization techniques for early cancer detection.

Opportunities

The massive and growing liquid biopsy market, particularly for breast cancer screening, presents a significant opportunity.

A successful blood-based test could improve early detection rates and patient compliance compared to current methods.

Success with a first product could validate the platform and fund development of a broader pan-cancer detection test.

Risk Factors

High clinical and regulatory risk in validating assay performance for approval.

Intense competition from well-funded companies in the liquid biopsy space.

Dependence on raising sufficient capital as a pre-revenue, private company to complete costly clinical trials.

Competitive Landscape

ARNA operates in the highly competitive liquid biopsy and multi-cancer early detection (MCED) space, competing against large, well-capitalized players like Grail (Illumina), Exact Sciences, Guardant Health, and Freenome. These competitors have advanced platforms, substantial clinical datasets, and significant commercial infrastructure, posing a major challenge for a smaller company like ARNA.

More companies in Diagnostics & Precision Medicine →More companies in United States →